AANEM News Express

AANEM News Express

Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation

12/14/2016
 
Bryant A, Atkins H, Pringle CE, et al. Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol 2016;73:652-658.

Submitted by Niranjan N. Singh, MD, News Science Editorial Board
The authors report a series of seven patients (two of whom were seronegative) with severe myasthenia gravis treated with autologous hematopoietic stem cell transplantation. Patients were refractory to treatment with multiple treatment modalities including pyridostigmine, corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, intravenous immunoglobulin, plasma exchange, and thymectomy. The protocol included graft mobilization and purification, treatment with intensive conditioning chemotherapy, and graft reinfusion. All patients achieved complete stable remission with no residual myasthenia gravis symptoms or requirement for disease-modifying therapy.


Comment: Refractory myasthenia gravis accounts for 10% of disease. Hematopoietic stem cell transplantation offers a potential treatment option for patients in this group. It should be emphasized that this study is a retrospective case series, and that stem cell transplantation has not been studied in a prospective fashion in patients with myasthenia gravis.


About the AANEM News Science Editorial Board

The board helps to highlight significant, timely science news items for AANEM members. It reviews articles in journals and websites, identifies newsworthy items in the field, and writes article summaries.


View Related News Stories:

  Practice


Recent AANEM News

Recap: 2019 AMA House of Delegates Annual Meeting

Science News: Efficacy of Botulinum Toxin A for Treating Cramps in Diabetic Neuropathy

Science News: Diagnostic Sensitivity of Electrophysiology and Ultrasonography in Ulnar Neuropathies of Different Severity

Science News: Long-term Effect of Thymectomy Plus Prednisone Versus Prednisone Alone in Patients with Non-thymomatous Myasthenia Gravis: 2-year Extension of the MGTX Randomised Trial

AANEM Returns to Capitol for 6th Annual Hill Day





Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job